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I. INTRODUCTION
Cefovecin is an antibiotic of the cephalosporin class, licensed for the treatment of skin infections in cat and dogs. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs. The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses. The disadvantage is the durable presence of subtherapeutic concentrations in the weeks after the resolution of infections. This is associated with the development of resistance in microbes. It is effective, but should not be used in pregnant or lactating animals or in animals with a history of allergies to penicillin or cephalosporin drugs [1] . Cefovecin was first authorized for use in the European Union in June 2006 [2] , and was approved for use in the United States in June 2008 [3] . It is approved as a broad-spectrum, third-generation cephalosporin for subcutaneous injection lasting 14 days for treating skin and soft tissue infections [4] . Contraindications include known allergies to cefovecin or antibiotics containing β-lactam rings such as penicillin or cephalosporins. Adverse reactions can include anaphylaxis. It is not for use in humans and should be kept out of reach of children. Individuals with similar known allergies should avoid dermal contact when handling the drugs. Adverse reactions in dogs can include lethargy, decreased appetite, vomiting, diarrhea, blood in feces, and flatulence. Adverse reactions in cats can include vomiting, diarrhea, decreased appetite, lethargy, odd hyperactive behavior, and inappropriate urination. Mildly increased serum ALT and gamma glutamyl transferase have been noted [5] . The following adverse events were reported voluntarily during post-approval use of the product in dogs and cats: death, tremors/ataxia, seizures, anaphylaxis, acute pulmonary edema, facial edema, injection site reactions (alopecia, scabs, necrosis, and erythema), hemolytic anemia, salivation, pruritis, lethargy, vomiting, diarrhea, and inappetance [6] . was 92.4% effective against skin infections (secondary superficial pyoderma,abscesses, and infected wounds). In cats, it was 96.8% effective against skin infections [7] . Figure  1 shows the structure of cefovecin.
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II.
METHODOLOGY Protein preparation
The crystal structure of Pseudomonas aeruginosa lipase was obtained from the Protein Data Bank, PDB 1ex9 (Figure 2 ). The protein structure was subjected to a refinement protocol using Molegro Molecular Viewer [8] .
Designing of structural analogs of Cefovecin
The structure of cefovecin ( Figure 1 ) was drawn with ACD/ChemSketch software [9] . The structural analogues of cefovecin were developed with structural modifications with different substituents. The carboxylic group [COOH] group at of cefovecin was replaced with COCH3, CH3, NO2, CF3 and NH2 analogues. The structures were built with ACD/ChemSketch software and minimized with Arguslab software [10] .
Molecular docking
Molecular docking was performed using Patchdock [11] . Patchdock is a molecular docking algorithm based on shape complementarity principles. Refinement was done in Firedock [12, 13] and processed with Molegro molecular viewer [14] . Lipinski rule of 5 was evaluated using Sanjeevini: a freely accessible web-server for target directed lead molecule discovery [15] . To Estimated free energy of binding (FEB) of cefovecin and its analogues is shown in Table 1 . Crystal structure of Pseudomonas aeruginosa lipase is shown in Figure 2 . Cefovecin in complex with Pseudomonas aeruginosa lipase is shown in Figure 3 while the docked cefovecin analogues with Pseudomonas aeruginosa lipase are presented in Figures 4 -8 
III. RESULTS AND DISCUSSION

IV. CONCLUSION
The in silico binding energy of cefovecin and its analogues with Pseudomonas aeruginosa lipase showed that the reactions are feasible because of their negative values of free energy. The ability of these drugs to inhibit Pseudomonas aeruginosa lipase is assured. We therefore recommend the synthesis, characterization and clinical studies of these cefovecin derivatives.
